gms | German Medical Science

77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

24.05. - 28.05.2006, Mannheim

Investigations of the B-RAF-MAPK and PTEN/PI3K-Signaling Pathways in Melanoma

Untersuchungen der B-RAF-MAPK und PTEN/PI3K-Signaltransduktionswege in Melanomen

Meeting Abstract

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno060

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2006/06hno060.shtml

Veröffentlicht: 7. September 2006

© 2006 Affolter et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

The RAS-RAF-MEK-ERK cascade is an intracellular signaling pathway that controls cell fate. The pathway plays an important role in different types of cancer. In 50-70% of melanomas, MEK–ERK signaling is elevated due to B-RAF mutations. Altered V600E-B-RAF has 500-fold elevated kinase activity leading to constitutive MEK-ERK stimulation and therefore to proliferation and survival in cancer cells. Thus, B-RAF is an important and exciting therapeutic target.

The PTEN/PI3K-Akt cascade is another example for a signaling pathway that is often deregulated in melanoma.

We have investigated tumour and skin samples of melanoma patients on different clinical trials. The samples were analysed for alterations in the RAS/RAF/MEK/ERK and PTEN/PI3K-Akt pathways by direct sequencing and immunohistochemistry.

None of the samples showed mutations in N-Ras and K-Ras or PI3K. 5 out of 9 tumours analysed harboured mutations in B-RAF Exon 15. 9/9 and 6/9 melanoma samples expressed phosphorylated (pp-) MEK and phosphorylated (pp-) ERK in the cytoplasm. No correlation could be detected between mutational status and protein expression, however. Therefore pp-MEK and pp-ERK could not be used as surrogate markers to identify which cancers carried B-RAF mutations in this analysis. Furthermore our study did not give evidence that PI3K mutations might play a role in the development of melanomas.